Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atebimetinib (Primary) ; Cemiplimab (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immuneering

Most Recent Events

  • 21 Apr 2026 According to an Immuneering media release, data from an expanded cohort totaling 55 first-line patients, which includes the initial cohort of 34 patients that the company previously reported plus an additional 21 patients will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago, IL.
  • 07 Jan 2026 According to an Immuneering media release, the company plans to dose first patient in trial of atebimetinib in combination with Libtayo in non-small cell lung cancer in 2H 2026.
  • 07 Jan 2026 According to an Immuneering media release, the company will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on January 7, 2026, to discuss the data from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top